← Back to Search

Device

dTMS for Smoking Cessation in Schizophrenia

N/A
Waitlist Available
Research Sponsored by Stony Brook University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Meet DSM-5 criteria for schizophreniform, schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise specified (NOS)
Ages 18-60
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 times over 3 weeks
Awards & highlights

Study Summary

This trial will study how dTMS affects brain chemistry in people with schizophrenia, and how this might help reduce smoking in this vulnerable population. #schizophrenia #smoking #dTMS #PET #brainchemistry

Who is the study for?
This trial is for English-speaking adults aged 18-60 with schizophrenia or related conditions who smoke daily and want to reduce or quit. They must be able to consent, have a negative drug test (except for cannabis), and meet DSM-5 criteria for nicotine use disorder.Check my eligibility
What is being tested?
The study tests if deep transcranial magnetic stimulation (dTMS) affects synaptic density in the brain's insula region, measured by PET scans, and if it influences smoking behavior in schizophrenia patients.See study design
What are the potential side effects?
Possible side effects of dTMS may include discomfort at the stimulation site, headache, lightheadedness, seizures (rare), hearing loss if ear protection isn't used during treatment.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with a schizophrenia spectrum disorder.
Select...
I am between 18 and 60 years old.
Select...
I am diagnosed with a nicotine addiction and want to reduce or stop smoking.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 times over 3 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 times over 3 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Insula synaptic density
Insula-centric functional connectivity
Smoking self-administration
Secondary outcome measures
Cigarettes per Day
Nicotine Craving
Symptoms of Psychosis

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active deep transcranial magnetic stimulation (dTMS)Experimental Treatment1 Intervention
Each treatment consists of 60 trains, each lasting 3 sec and interleaved with a 15 sec delay. The entire treatment is delivered over 20 min. The treatment goes for 5 days/week and for a total of 3 weeks.
Group II: ShamPlacebo Group1 Intervention
Active and sham cards do not differ in appearance, and both coils are enclosed within the same helmet, enabling double-blind administration. The same procedure will be done, the only difference is that the sham card does not deliver any stimulation.

Find a Location

Who is running the clinical trial?

Stony Brook UniversityLead Sponsor
213 Previous Clinical Trials
39,489 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,447 Previous Clinical Trials
2,594,028 Total Patients Enrolled
50 Trials studying Schizophrenia
5,129 Patients Enrolled for Schizophrenia

Media Library

Active deep transcranial magnetic stimulation (dTMS) (Device) Clinical Trial Eligibility Overview. Trial Name: NCT05724810 — N/A
Schizophrenia Research Study Groups: Active deep transcranial magnetic stimulation (dTMS), Sham
Schizophrenia Clinical Trial 2023: Active deep transcranial magnetic stimulation (dTMS) Highlights & Side Effects. Trial Name: NCT05724810 — N/A
Active deep transcranial magnetic stimulation (dTMS) (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05724810 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this clinical trial consider geriatric individuals as participants?

"This experiment seeks individuals aged 18 or more and under 60 for inclusion."

Answered by AI

Are there still openings for potential participants in this investigation?

"As per the information stored on clinicaltrials.gov, this experiment is not presently recruiting volunteers. Originally posted on February 1st 2023 and last updated January 27th 2023, though there are 530 other studies actively enrolling patients now."

Answered by AI

May I have the opportunity to partake in this exploration?

"The ideal candidate for this research is between 18 and 60 years old, with a schizophrenia diagnosis. As of now, the study requires 38 individuals to participate."

Answered by AI

Who else is applying?

What site did they apply to?
Stony Brook University
What portion of applicants met pre-screening criteria?
Did not meet criteria
~25 spots leftby Aug 2027